Sanger Sequencing Versus INNO-LiPA® HBV PreCore Assay for Routine Detection of Precore and Basal Core Promoter Mutations in Hepatitis Virus B Chronically Infected Patients

We compared the Sanger sequencing and the commercial INNO-LiPA® HBV assay for the routine detection of precore (PC) and basal core promoter (BCP) mutations of hepatitis B virus in chronically infected patients. The overall agreement rate between assays was 94.2% and 98.8% for the detection of PC and BCP mutations, respectively.